EICHORCondition: Systemic Lupus Erythematosus · Sponsor: Novartis Pharmaceuticals
The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Pinnacle Research Group Llc | Anniston, Alabama, United States | — |
| Providence Medical Center | Burbank, California, United States | — |
| University of California San Diego | La Jolla, California, United States | — |
| Millennium Clinical Trials | Westlake Village, California, United States | — |
| University of Colorado | Aurora, Colorado, United States | — |
| Yale University School Of Medicine | New Haven, Connecticut, United States | — |
| Clinical Res Of W Florida | Clearwater, Florida, United States | — |
| GNP Research | Cooper City, Florida, United States | — |
| Clinical Research of West Florida Inc | Tampa, Florida, United States | — |
| Parris and Associates Rheumatology | Lawrenceville, Georgia, United States | — |
| Chicago Clinical Research Inst | Chicago, Illinois, United States | — |
| Robert A Hozman MD SC | Skokie, Illinois, United States | — |
+ 123 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05639114